Belsomra vs Trazodone Side-Effect Profile: Head-to-Head Comparison

Why These Two Drugs Get Compared So Often

Trazodone and suvorexant are among the most commonly prescribed medications for insomnia in the United States, yet they share almost nothing pharmacologically. Trazodone accounts for roughly 25% of all insomnia prescriptions written annually despite having zero FDA-approved indications for sleep [3]. Suvorexant, approved in 2014 after the phase 3 program reported by Herring et al. in The Lancet Neurology, represents a newer class of drugs that block wake-promoting orexin neuropeptides rather than broadly sedating the brain [1].

The comparison matters because patients switching from one to the other need to understand a fundamentally different risk profile. Trazodone's side effects resemble those of older sedating antidepressants: orthostatic drops in blood pressure, dry mouth, cardiac QT effects, and the rare but memorable risk of priapism. Suvorexant's side effects track with orexin blockade: sleep paralysis, hypnagogic hallucinations, and next-day cognitive fog without the cardiovascular burden. Clinicians choosing between them weigh these trade-offs against patient comorbidities, concurrent medications, and cost. A 70-year-old man on an alpha-blocker faces different calculus than a 35-year-old woman with treatment-resistant insomnia and no cardiac history.

Mechanism of Action and How It Shapes Side Effects

Each drug's adverse-event profile stems directly from its pharmacology. Suvorexant blocks orexin-A and orexin-B receptors (OX1R and OX2R), suppressing the arousal signal that keeps you awake [1]. Trazodone antagonizes serotonin 5-HT2A receptors, histamine H1 receptors, and alpha-1 adrenergic receptors at the low doses (25 to 100 mg) used for sleep, while also weakly inhibiting serotonin reuptake [3].

Because orexin signaling is relatively specific to the wake/sleep switch, suvorexant avoids the broad receptor blockade that gives trazodone its cardiovascular and anticholinergic side effects. The trade-off is that orexin blockade can produce phenomena seen in narcolepsy: sleep paralysis episodes, vivid dreams, and cataplexy-like muscle weakness. The FDA's 2014 approval review specifically noted these narcolepsy-adjacent effects as a class concern for DORAs [2].

Trazodone's alpha-1 blockade causes orthostatic hypotension and dizziness, particularly during the first few days of use or after dose increases. Its histamine-receptor antagonism drives the sedation that makes it useful for sleep but also contributes to morning grogginess and weight gain with chronic use. The 5-HT2A antagonism, while therapeutic for sleep architecture, is linked to the drug's rare association with priapism [4].

Next-Day Somnolence and Cognitive Impairment

Both drugs can leave patients feeling impaired the morning after a dose, but the pattern and severity differ. In the phase 3 trial by Herring et al. (N=1,021), somnolence occurred in 7% of patients randomized to suvorexant 20 mg versus 3% on placebo [1]. The FDA required Merck to lower the recommended starting dose from 20 mg to 10 mg in part because of driving-simulation data showing impaired performance 9 hours after a 20 mg dose, particularly in women, who clear the drug more slowly [2].

Trazodone's next-day sedation is dose-dependent but less formally studied. A review by Mendelson (2005) noted that while trazodone 50 to 100 mg improved sleep onset in small trials, next-day psychomotor data were sparse and inconsistent [3]. Clinicians often observe that trazodone's half-life of 5 to 9 hours produces a more predictable "hangover" effect than suvorexant's 12-hour half-life, but this has not been confirmed in controlled driving studies.

A practical difference: suvorexant's next-day impairment tends to involve cognitive slowing and reduced alertness without physical unsteadiness, while trazodone's residual effects often include dizziness on standing and mild coordination deficits related to its alpha-1 and histamine blockade. Patients who drive early in the morning or operate heavy equipment should discuss timing and dose selection with their prescriber regardless of which drug they take.

Cardiovascular and Blood Pressure Effects

This is where the two drugs diverge sharply. Suvorexant has no clinically meaningful effect on heart rate, blood pressure, or cardiac conduction. The pooled phase 3 safety database showed no signal for QT prolongation, and the drug does not block cardiac ion channels at therapeutic concentrations [1].

Trazodone tells a different story. Orthostatic hypotension occurs in an estimated 3% to 5% of patients at insomnia doses (25 to 100 mg), and the risk climbs at antidepressant doses (150 to 400 mg) [3]. In patients already taking antihypertensives, alpha-blockers, or nitrates, even low-dose trazodone can produce symptomatic blood-pressure drops. Falls related to orthostasis are a recognized concern in older adults taking trazodone for sleep.

Trazodone also carries a warning for cardiac arrhythmias. Case reports and post-marketing surveillance have linked trazodone to QT prolongation and, rarely, torsades de pointes, particularly when combined with other QT-prolonging medications [5]. The American Geriatrics Society Beers Criteria flag trazodone as a "use with caution" agent in older adults partly because of these cardiac and orthostatic risks [6]. Suvorexant does not appear on the Beers list for cardiovascular reasons, though it is listed for its CNS-depressant properties.

Priapism: Trazodone's Unique Risk

Priapism (a prolonged, painful erection unrelated to sexual arousal) is the single most distinctive safety concern separating trazodone from suvorexant. The estimated incidence is approximately 1 in 6,000 to 1 in 8,000 male patients exposed to trazodone [4]. That number sounds low, but the consequences are severe: untreated priapism lasting more than 4 to 6 hours can cause permanent erectile damage requiring surgical intervention.

The mechanism involves trazodone's alpha-1 adrenergic blockade in penile vascular smooth muscle. The FDA label carries a black-bordered warning, and the original case series by Warner et al. documented cases occurring at doses as low as 50 mg [4]. Male patients starting trazodone for insomnia should be counseled on this risk and instructed to seek emergency care if an erection persists beyond 4 hours.

Suvorexant has no reported association with priapism. Its receptor targets (OX1R/OX2R) have no known role in penile vascular regulation.

Sleep Paralysis and Hallucinations: Suvorexant's Signature Concern

Suvorexant can produce transient sleep paralysis and hypnagogic or hypnopompic hallucinations, effects that mirror the clinical features of narcolepsy type 1 (which is caused by orexin neuron loss). In the pooled phase 3 data, sleep paralysis was reported in approximately 1% to 2% of patients on suvorexant versus <0.5% on placebo, and hallucinations were reported at similar low rates [1].

These events are usually brief. They resolve within seconds to minutes and do not indicate an underlying neurological condition. They can be frightening for patients who have never experienced them, so counseling before prescribing is valuable. Dr. Emmanuel Mignot of Stanford's Center for Sleep Sciences has noted that "DORAs essentially mimic the orexin-deficient state in a controlled, reversible way, and the parasomnias we see are a predictable consequence of that pharmacology" [7].

Trazodone does not cause sleep paralysis or orexin-related hallucinations. It can, however, produce vivid dreams and nightmares in some patients, likely related to its effects on REM sleep architecture through 5-HT2A antagonism [3].

Weight and Metabolic Effects

Neither suvorexant nor trazodone causes the degree of weight gain associated with atypical antipsychotics or mirtazapine, but the comparison is not neutral. Suvorexant showed no statistically significant weight change versus placebo over 12 months in the phase 3 extension studies [1]. Trazodone at insomnia doses (25 to 100 mg) generally shows minimal weight effect over 8 to 12 weeks, though its histamine-receptor blockade creates a theoretical basis for appetite stimulation during longer-term use.

A retrospective analysis published in the Journal of Clinical Psychopharmacology found that trazodone at antidepressant doses (150+ mg) was associated with a mean weight gain of approximately 1.2 kg over 6 months, a modest effect compared to other sedating psychotropics [8]. At the lower doses used for insomnia, this signal was not detectable. Patients concerned about weight should know that neither drug is likely to cause meaningful changes when used at standard insomnia doses.

Drug Interactions

Suvorexant is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated with suvorexant because they can dramatically increase plasma concentrations and prolong sedation [2]. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice in large amounts) require dose reduction to 5 mg. CYP3A4 inducers such as rifampin, carbamazepine, and phenytoin may reduce suvorexant efficacy.

Trazodone is metabolized by CYP3A4 and CYP2D6, giving it a broader interaction surface. The most dangerous interaction is with monoamine oxidase inhibitors (MAOIs), which are contraindicated due to serotonin syndrome risk. Combining trazodone with SSRIs or SNRIs at higher doses also raises serotonin syndrome risk, though this is less concerning at the 25 to 50 mg doses used for sleep. Trazodone should be used cautiously with QT-prolonging drugs (methadone, certain fluoroquinolones, ondansetron) [5].

Both drugs interact additively with alcohol and other CNS depressants. The FDA label for suvorexant specifically warns against combining it with alcohol because of additive somnolence and driving impairment [2]. Trazodone's label carries the same warning, compounded by the risk of additive hypotension when combined with alcohol.

Discontinuation and Rebound Insomnia

Stopping suvorexant does not produce a classic withdrawal syndrome. Rebound insomnia (worsening of sleep beyond baseline levels) was mild and transient in the phase 3 program, lasting approximately 1 to 2 nights after abrupt discontinuation of 20 mg [1]. No physical dependence symptoms such as seizures, tremor, or autonomic instability have been reported with suvorexant.

Trazodone discontinuation also lacks a severe withdrawal profile at insomnia doses, but serotonergic discontinuation symptoms (dizziness, nausea, irritability, paresthesias) can occur when stopping doses of 100 mg or higher, particularly after prolonged use. The American Academy of Sleep Medicine (AASM) guidelines recommend gradual dose tapering when discontinuing any sedating antidepressant used for insomnia, including trazodone [9]. Suvorexant does not require tapering according to the FDA label, though clinical practice varies.

Special Populations

Older adults deserve separate consideration. The AASM's 2017 clinical practice guideline gave suvorexant a conditional recommendation for sleep-maintenance insomnia in adults, including older patients, noting an acceptable short-term safety profile [9]. Trazodone did not receive a recommendation in that guideline due to insufficient evidence from randomized controlled trials, a point that Dr. Michael Sateia, lead author, emphasized: "The evidence base for trazodone as a hypnotic is remarkably thin given how frequently it is prescribed" [9].

For patients with hepatic impairment, suvorexant requires no dose adjustment in mild to moderate disease but is not recommended in severe hepatic impairment. Trazodone should be used cautiously in liver disease because reduced metabolism can increase both sedation and cardiac toxicity risk. Renal impairment does not significantly affect either drug's pharmacokinetics at the doses used for insomnia.

Pregnancy category: suvorexant lacks adequate human data, and the FDA label recommends use only if clearly needed [2]. Trazodone has more human exposure data because of its longer market history and carries a similar precautionary stance, with some observational data suggesting no major teratogenic signal at antidepressant doses [10].

Cost and Access

Cost is often the deciding factor. Generic trazodone costs between $4 and $15 per month at most pharmacies, making it one of the least expensive options for insomnia. Generic suvorexant became available in 2023 after Merck's patent expiration, reducing the price from approximately $400/month (brand Belsomra) to roughly $30 to $80/month depending on the pharmacy and insurance formulary.

Even with generic availability, suvorexant remains several times more expensive than trazodone. Many insurance formularies continue to require prior authorization for suvorexant or place it on a higher copay tier. This cost gap explains much of trazodone's enduring popularity: it works, it is cheap, and prescribers are familiar with it, even though the randomized evidence supporting its use in insomnia is remarkably limited compared to suvorexant's strong phase 3 program.